CCR9 Antagonists in the Treatment of Ulcerative Colitis

Figure 5

Pharmacological CCR9 inhibition results in a significant improvement in colonic inflammation in mdr1a^−/− mice. (a) CCX025 treatment resulted in significantly lower levels of the proinflammatory cytokines IFN-γ, IL-1β, and IL-6 in the colon; at the same time CCX025 treatment resulted in a significant elevation in the levels of the anti-inflammatory cytokine IL-10 in the colon ( = 16–19). (b) CCX025 treatment, starting at 11 weeks of age, resulted in a significant reduction in the weight-to-length ratio of the colon in mdr1a^−/− mice, compared to vehicle-treated mice (). CCX025 treatment resulted in significantly reduced histological damage scores in the proximal colon (c) and the distal colon (d). All panels: < 0.05; < 0.01.

(a)

(b)

(c)

(d)